文献速递白血病

成人NUP98重排急性髓系白血病的综合突变谱与临床结局

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.
PubMed 文献 · Leukemia · 2026-05-12

该研究报告95例NUP98重排成人AML患者,中位年龄50岁,NUP98::NSD1融合最常见(54%)。全队列中位OS 15.2个月,中位EFS 5.8个月;强化治疗患者中年龄、FLT3抑制剂和移植影响OS。NUP98r预后类似NUP98野生型ELN adverse患者,但FLT3抑制剂治疗可改善预后,5年OS达53.3%。

要点

  • NUP98r成人AML中位OS为15.2个月,中位EFS为5.8个月。
  • NUP98::NSD1融合最常见(54%),患者更年轻且FLT3-ITD和WT1突变率更高。
  • 强化治疗中年龄、FLT3抑制剂和造血干细胞移植影响OS。

核心结论

  • NUP98r成人AML预后类似NUP98野生型ELN adverse患者,但FLT3抑制剂治疗可改善预后。

研究设计与样本

  • 报告95例携带NUP98重排的成人急性髓系白血病患者队列。

主要发现

  • 全队列中位OS为15.2个月(95% CI,11.9-20.8),中位EFS为5.8个月(2-7.5)。
  • NUP98::NSD1融合最常见(54%),该亚组更年轻(41岁 vs. 61岁),de novo AML比例更高(94% vs. 64%)。
  • NUP98::NSD1亚组正常核型率更高(56% vs. 4.5%),FLT3-ITD(76% vs. 18%)和WT1突变(50% vs. 16%)更常见。
  • 强化治疗患者(n=73)中,年龄(HR=2.7)、FLT3抑制剂治疗(HR=0.45)和造血干细胞移植(HR=0.5)影响OS。
  • NUP98r患者中位OS类似NUP98野生型ELN adverse患者,初始分类为intermediate者20.3个月(11.7-30.2),adverse者15.7个月(13.5-42.9)。

关键数值与推荐

  • FLT3抑制剂治疗组中位OS未达到,5年OS为53.3%,接近intermediate-risk患者。

临床怎么用

  • 对NUP98r成人AML应进行综合突变谱检测,关注FLT3-ITD和WT1突变。
  • 强化治疗时可考虑联合FLT3抑制剂及评估造血干细胞移植以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a large cohort of 95 adult patients with acute myeloid leukemia (AML) harboring NUP98 rearrangements (NUP98r). Patient characteristics included a young age (median 50 years [IQR 38-64]), 20% of therapy-related AML, a high WBC count (median 52×109/L), normal karyotype in 32%, FLT3-ITD in 48% and WT1 mutations in 34%. NUP98::NSD1 fusion was the most common (54%), and these patients were significantly younger (41 y vs. 61 y), had more de novo AML (94% vs. 64%), higher rates of normal karyotypes (56% vs. 4.5%), FLT3-ITD (76% vs. 18%) and WT1 mutations (50% vs. 16%) than other NUP98r AML. The median overall survival (OS) for the entire cohort was 15.2 months (95% CI, 11.9-20.8) and event-free survival was 5.8 months (2-7.5). Among patients treated intensively (n = 73), age (HR = 2.7), FLT3 inhibitor therapy (HR = 0.45) and hematopoietic stem cell transplant (HR = 0.5) influenced OS in univariate analysis. Compared with NUP98 wild-type (WT) AML, NUP98r patients had a prognosis more similar to that of NUP98 WT ELN adverse patients whether initially classified as intermediate (20.3 months [11.7-30.2]) or adverse (15.7 months [13.5-42.9]). However, treatment with FLT3 inhibitors improved prognosis, with median OS not reached and 5-year OS of 53.3%, approaching that of intermediate-risk patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ducourneau B, Pages A, Struski S, et al. Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement. Leukemia. 2026. PMID: 42120929. doi:10.1038/s41375-026-02973-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。